Little-known biotech company just had groundbreaking results from a study

Unsubscribe     NanoViricides, Inc (NNVC) Is Taking A Novel, Game-Changing Approach To Eradicating Many Respiratory Viruses Once And For All Including Tripledemic Threat Of COVID, RSV, FLU… As biotech stages a big comeback, one NYSE-traded company looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology. This global leader in broad-spectrum antiviral nanomedicines had remarkable news recently, revealing that the antiviral activity of its NV-387 oral treatment against RSV/A2 is strong enough to have resulted in full survival of lethally infected animals. The company believes the NV-387 oral treatment is capable of curing RSV infection. Why is this important? Because there is currently no approved treatment for RSV other than ribavirin. A safe and effective treatment remains an unmet medical need! RSV is an important disease in infants and children less than 5 years old, as well as in older persons over 65 years old. According to the CDC, each year in the United States, RSV leads to approximately 58,000-80,000 hospitalizations of children younger than 5 years old and 100-300 deaths in children younger than 5 years old. It also leads to 60,000-160,000 hospitalizations among adults 65 and older, and 6,000-10,000 deaths of adults 65 and older.  Ribavirin is the only currently approved drug for RSV infection, that can be used only as a last resort because of its extensive toxicity that limits its effectiveness. This company's study has achieved an extremely significant result in the fight against RSV! Learn how this company could see tremendous growth ahead with a novel broad-spectrum antiviral that has activity against RSV!

This email was sent to edwardlorilla1986.paxforex@blogger.com by editor@marketmovingtrends.com MarketMovingTrends c/o CLM Media LLC, 45 South Park Place, #203, Morristown, NJ 07960 United States   Unsubscribe | Report Spam